Jounce Therapeutics Reports Second Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Jounce Therapeutics (JNCE) Tops Q2 EPS by 4c
August 9, 2017 6:32 AM EDTJounce Therapeutics (NASDAQ: JNCE) reported Q2 EPS of ($0.11), $0.04 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $20.29 million versus the consensus estimate of $19.94 million.
Jounce reiterates the financial guidance previously provided for the full year 2017. Based on its current operating... More
